title: [Efficacy of tyrosine kinase inhibitor in treatment of chronic myeloid leukemia patients].
abstract: OBJECTIVE
  To evaluate the effects of tyrosine kinase inhibitors (TKI) in the treatment of chronic myeloid leukemia.
  
  
  METHODS
  There were total 655 cases of chronic myeloid leukemia treated in one single-institution enrolled in this study. The dosage of TKI Imatinib was 400 mg/d for chronic phase, 600 mg/d for accelerated and blast phase respectively. Complete blood count, cytogenetic and molecular studies were regularly monitored during the course of therapy. The therapeutic effect was evaluated and the survival analysis was performed.
  
  
  RESULTS
  The total complete hematologic response (CHR), major cytogenetic response (MCyR), complete cytogenetic response (CCyR) and major molecular response (MMR) rates were 92.1%, 75.8%, 73.1% and 47.9% respectively. 1-year, 3-year, 5-year and 10-year overall survival (OS) rates were (96.3 +/- 0.8)%, (86.3 +/-1.8)%, (79.0 +/- 2.4)% and (66.5 +/- 4.8)% respectively. 1 year, 3-year, 5-year and 10-year event-free survival (EFS) rates were (92.2 +/- 1.1)%, (77.9 +/- 2.1)%, (67.9 +/- 6.8)% and (35.8 +/- 6.0)% respectively. The proportion of the patients in chronic phase achieving CHR, MCyR, CCyR and MMR were 98.7%, 82.5%, 79.4% and 52.4% respectivly. Compared with chronic phase patients, the efficacy of IM in the treatment of accelerated phase and blast phase patients was significantly lower. The effect of TKI in early chronic phase was better than that in late chronic phase. Early molecular response was associated with a better 5-year EFS, but not OS.
  
  
  CONCLUSIONS
  CML patients in chronic phase treated with TKI have a better outcome. The earlier TKI be used, the better the prognosis and efficacy be achieved.
authors.forename: Xiang-Long
authors.initials: XL
authors.lastname: Li
authors.forename: Huan-Ling
authors.initials: HL
authors.lastname: Zhu
authors.forename: Hong-Ying
authors.initials: HY
authors.lastname: Liu
authors.forename: Su-Juan
authors.initials: SJ
authors.lastname: Lü
authors.forename: Su-Ping
authors.initials: SP
authors.lastname: Zheng
authors.forename: Yu
authors.initials: Y
authors.lastname: Wu
authors.forename: Ting
authors.initials: T
authors.lastname: Niu
authors.forename: Ting
authors.initials: T
authors.lastname: Liu
mesh_terms: D001549:Benzamides / Q000627:therapeutic use*; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D010879:Piperazines / Q000627:therapeutic use*; D011379:Prognosis; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases; D011743:Pyrimidines / Q000627:therapeutic use*; D012074:Remission Induction; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases